Research programme: hepatitis B therapeutics - Arcturus/Janssen Pharmaceuticals

Drug Profile

Research programme: hepatitis B therapeutics - Arcturus/Janssen Pharmaceuticals

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arcturus Therapeutics
  • Developer Arcturus Therapeutics; Janssen Pharmaceuticals
  • Class MicroRNAs; RNA; Small interfering RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 19 Oct 2017 Arcturus Therapeutics has patents pending for LUNAR lipid-mediated delivery and UNA technology including UNA oligomers in USA, Europe, Japan, China and other countries
  • 11 Nov 2016 Preclinical trials in Hepatitis B in USA (Parenteral)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical study in Hepatitis B presented at the Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top